Related references
Note: Only part of the references are listed.SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer
Qing Shi et al.
CELL DEATH AND DIFFERENTIATION (2022)
SPOP mutation induces DNA methylation via stabilizing GLP/G9a
Jianong Zhang et al.
NATURE COMMUNICATIONS (2021)
SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition
Jian Ma et al.
NATURE COMMUNICATIONS (2021)
Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP HIPK2 axis
Xiaofeng Jin et al.
NUCLEIC ACIDS RESEARCH (2021)
CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling
Xiaofeng Jin et al.
LEUKEMIA (2020)
Technical report: Targeted proteomic analysis reveals enrichment of atypical ubiquitin chains in contractile murine tissues
Tiaan Heunis et al.
JOURNAL OF PROTEOMICS (2020)
Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells
Chien-Hung Yeh et al.
MOLECULAR CANCER (2020)
K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
Qing Yin et al.
NATURE COMMUNICATIONS (2019)
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly
Qing Shi et al.
MOLECULAR CANCER (2019)
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
Rui Ma et al.
BRITISH JOURNAL OF CANCER (2018)
TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis
Qiushi Wang et al.
CANCER RESEARCH (2018)
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
Azad Saei et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Matthew Dankner et al.
ONCOGENE (2018)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer
Xiaofeng Jin et al.
PLOS GENETICS (2017)
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling
Mirjam Blattner et al.
CANCER CELL (2017)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling (vol 30, pg 485, 2016)
Zoi Karoulia et al.
CANCER CELL (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover
P. Zhang et al.
CELL DEATH & DISEASE (2015)
Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
Chuandong Geng et al.
CANCER RESEARCH (2014)
Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer
Jean-Philippe P. Theurillat et al.
SCIENCE (2014)
Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants
Jian An et al.
CELL REPORTS (2014)
Building and remodelling Cullin-RING E3 ubiquitin ligases - 'Ubiquitylation: mechanism and functions' review series
John R. Lydeard et al.
EMBO REPORTS (2013)
Ring Finger Protein 149 Is an E3 Ubiquitin Ligase Active on Wild-type v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Seung-Woo Hong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes
Matthieu Le Gallo et al.
NATURE GENETICS (2012)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Christopher E. Barbieri et al.
NATURE GENETICS (2012)
Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1
C. Li et al.
ONCOGENE (2011)
Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases
Min Zhuang et al.
MOLECULAR CELL (2009)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Ubiquitin transfer from the E2 perspective - Why is UbcH5 so promiscuous?
Peter S. Brzovic et al.
CELL CYCLE (2006)
Low frequency of BRAF mutations in endometrial and in cervical carcinomas
Gerna Moreno-Bueno et al.
CLINICAL CANCER RESEARCH (2006)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)